Free Trial

Millennium Management LLC Invests $1.14 Million in Nature's Sunshine Products, Inc. (NASDAQ:NATR)

Nature's Sunshine Products logo with Medical background

Millennium Management LLC purchased a new position in shares of Nature's Sunshine Products, Inc. (NASDAQ:NATR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 77,443 shares of the company's stock, valued at approximately $1,135,000. Millennium Management LLC owned approximately 0.42% of Nature's Sunshine Products as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in Nature's Sunshine Products during the 4th quarter worth approximately $41,000. Amundi acquired a new position in Nature's Sunshine Products during the fourth quarter worth $63,000. Deutsche Bank AG purchased a new position in Nature's Sunshine Products in the fourth quarter worth $103,000. Wells Fargo & Company MN raised its position in Nature's Sunshine Products by 28.8% in the fourth quarter. Wells Fargo & Company MN now owns 7,209 shares of the company's stock worth $106,000 after acquiring an additional 1,611 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Nature's Sunshine Products by 346.9% in the fourth quarter. BNP Paribas Financial Markets now owns 11,719 shares of the company's stock valued at $172,000 after acquiring an additional 9,097 shares during the period. Institutional investors and hedge funds own 79.40% of the company's stock.

Nature's Sunshine Products Stock Down 0.3%

Shares of NATR traded down $0.05 on Friday, reaching $14.51. The stock had a trading volume of 34,697 shares, compared to its average volume of 46,193. Nature's Sunshine Products, Inc. has a twelve month low of $10.81 and a twelve month high of $18.06. The firm has a market capitalization of $266.27 million, a PE ratio of 16.49 and a beta of 1.10. The firm has a 50-day moving average of $13.07 and a 200 day moving average of $14.08.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.09. Nature's Sunshine Products had a return on equity of 11.08% and a net margin of 3.81%. The company had revenue of $113.25 million for the quarter, compared to analyst estimates of $109.39 million.

Analyst Ratings Changes

Separately, DA Davidson reaffirmed a "buy" rating and set a $19.00 price target on shares of Nature's Sunshine Products in a research note on Tuesday.

View Our Latest Report on NATR

About Nature's Sunshine Products

(Free Report)

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.

Featured Articles

Institutional Ownership by Quarter for Nature's Sunshine Products (NASDAQ:NATR)

Should You Invest $1,000 in Nature's Sunshine Products Right Now?

Before you consider Nature's Sunshine Products, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nature's Sunshine Products wasn't on the list.

While Nature's Sunshine Products currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines